<DOC>
	<DOCNO>NCT02818751</DOCNO>
	<brief_summary>Neurofunctional Predictors Escitalopram Treatment Response Adolescents Anxiety . To determine effect escitalopram functional activation pattern Continuous Performance Task Emotional Neutral Distracters , CPT-END . To examine baseline functional activity functional connectivity profile ventrolateral prefrontal cortex marker subsequent treatment response escitalopram adolescent generalize anxiety disorder ( GAD ) . To use proton magnetic resonance spectroscopy ( 1H MRS ) examine glutamatergic γ-aminobutyric acid ( GABA ) -related abnormality anterior cingulate adolescent GAD compare healthy adolescent .</brief_summary>
	<brief_title>Neurofunctional Predictors Escitalopram Treatment Response Adolescents With Anxiety</brief_title>
	<detailed_description>The long-term goal study explore neurobiological basis generalize anxiety disorder ( GAD ) use validate functional MRI ( fMRI ) paradigm functional connectivity analyse cohort GAD patient healthy subject generate feasibility preliminary data regard treatment-related effect escitalopram brain functional activation Fc pattern pediatric GAD . An additional goal identify biological marker saliva urine predict treatment response pediatric subject GAD . The central hypothesis proposal core dysfunction within prefrontal-amygdala network , investigator others observe GAD , normalized successful treatment . The rationale underlying hypothesis , despite high prevalence GAD , need understand neurobiology identify biomarkers treatment response mechanisms selective serotonin reuptake inhibitor ( SSRIs ) putatively effect change neurocircuitry pediatric GAD .</detailed_description>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Inclusion Anxiety Subjects : Diagnostic Statistical ManualIV ( Text Revision ) criterion generalize anxiety disorder diagnose Anxiety Disorders Interview Schedule ( ADISIV ) Baseline Pediatric Anxiety Rating Scale ( PARS ) score ≥15 baseline Ages 1217 year 11 month old Fluent English Provision write informed consent legal guardian write assent subject Tanner scale stage IIV , order include postpubescent subject minimize brain change associate onset puberty Does history intolerance , nonresponse hypersensitivity escitalopram No cooccurring Diagnostic Statistical ManualIV ( Text Revision ) diagnosis mood ( except dysthymia , depression otherwise specify ) , eat , pervasive developmental disorder psychotic disorder Subjects exclude lifetime diagnosis mental retardation ( intelligence quotient &lt; 70 ) Subjects history alcohol drug dependence alcohol abuse within past 6 month ( nicotine dependence permit ) exclude No new psychotherapy permit study participation patient engage psychotherapy , must stable 1 month prior baseline Females eligible participate pregnant , breast feeding lactating . Inclusion Healthy Subjects : Ages 1217 year 11 month No history Diagnostic Statistical ManualIV ( Text Revision ) Axis I disorder ( nicotine dependence permit ) No firstdegree relative affective psychotic disorder No medication central nervous system effect within 5 halflives Fluent English Tanner stage IIV Provision inform consent assent . Exclusion Generalized Anxiety Disorder Patients &amp; Healthy Subjects : Contraindication magnetic resonance imaging ( MRI ) scan ( e.g. , brace claustrophobia ) An unstable medical neurological illness could influence fMRI magnetic resonance spectroscopy result Subjects exclude lifetime diagnosis mental retardation intelligence quotient &lt; 70 ) A positive pregnancy test Adolescents exclude treatment medication central nervous system effect require 5 day screen period order minimize length time screen baseline maximize patient safety , recognize long taper period require medication Adolescents history major medical neurological disorder may result neurofunctional neurochemical abnormality include loss consciousness &gt; 10 minute exclude No cooccurring Diagnostic Statistical ManualIV ( Text Revision ) diagnosis mood ( dysthymia Depression Not Otherwise Specified ) , eat , pervasive developmental disorder psychotic disorder Subjects exclude lifetime diagnosis mental retardation intelligence quotient &lt; 70 Subjects history alcohol drug dependence alcohol abuse within past 6 month ( nicotine dependence permit ) exclude No new psychotherapy permit study participation patient engage psychotherapy , must stable 1 month prior baseline Females eligible participate pregnant , breast feeding lactate The patient live &gt; 100 mile University Cincinnati able attend followup visit</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Anxiety</keyword>
	<keyword>Adolescents Anxiety</keyword>
</DOC>